Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00941980 · ClinicalTrials.gov registry record
Osteocel® Plus in Posterior Lumbar Interbody Fusion (PLIF)
A clinical trial, sponsored by NuVasive.
- Completed
- Registry status
- 28
- Enrollment target
NCT00941980: Completed study, sponsored by NuVasive.
NCT00941980 is a clinical trial that has completed, run by NuVasive. The registered enrollment target is 28 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00941980 has completed, sponsored by NuVasive.
- COMPLETED
- Registry status
- 28 participants
- Enrollment target
Study Summary
This study is being conducted to determine the percentage of patients with solid spinal fusions after being treated with Osteocel Plus in a PLIF procedure. Due to the unique processing conditions, Osteocel Plus retains a high concentration of stem cells attached to the allograft bone matrix, so it is hypothesized that the fusion rate with Osteocel Plus will be comparable to published data for autograft. The Osteocel product family has already been used in approximately 20,000 cases worldwide.
Interventions
- BIOLOGICAL Osteocel Plus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2009-06 |
| Est. Completion | 2012-10 |
What the finished NCT00941980 record still lists
NCT00941980 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 28 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Osteocel Plus is the first listed.
NCT00941980 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00941980 about?
NCT00941980 is a clinical study titled "Osteocel® Plus in Posterior Lumbar Interbody Fusion (PLIF)". This study is being conducted to determine the percentage of patients with solid spinal fusions after being treated with Osteocel Plus in a PLIF procedure. Due to the unique processing conditions, Osteocel Plus retains a high concentration of stem cells attached to the allograft bone matrix, so it i...
What is the current status of trial NCT00941980?
This trial is currently completed. The enrollment target is 28 participants. The study started on 2009-06. Estimated completion is 2012-10.
What interventions are being tested in trial NCT00941980?
The interventions under investigation include: Osteocel Plus (BIOLOGICAL).
Who is sponsoring clinical trial NCT00941980?
This trial is sponsored by NuVasive, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia